Novartis and and generic drug maker Pharmacor have resolved litigation over the Swiss pharmaceutical giant’s patents for blockbuster MS drug Gilenya.
French drug giant Sanofi has appealed a decision giving American biopharmaceutical company Amgen the go-ahead for its patents for a cholesterol-lowering antibody that could be used to treat heart disease, diabetes, stroke and Alzheimer’s.
A judge has found mining tool company Globaltech and mineral exploration company Boart Longyear infringed a patent for a mining tool owned by Australian Mud Company.
A judge has thrown out competing appeals of a decision finding Pfizer’s patent for its post-operative injectable painkiller Dynastat is valid and that Australian drug maker Juno Pharmaceuticals infringed the patent by selling generic versions of the drug in Australia.
Gaming giant Aristocrat Technologies has lost its legal challenge to a decision that rejected a patent for its popular Lightning Link electronic poker machine, after six High Court Justices were equally split on whether it could be patented.
Bristol-Myers Squibb unit Celgene and two generic drug makers have withdrawn an application for ACCC approval of a patent settlement that would have allowed for an early launch of a generic version of blockbuster cancer drug Revlimid.
German pharmaceutical giant Bayer, which is facing a legal bid by generic drug maker Sandoz to invalidate patents covering blood clot drug Xarelto, is seeking to amend one of the patents in dispute.
An Australian non-practicing entity alleging Apple’s Touch ID and Face ID technology infringes its patents has accused the Silicon Valley company of refusing to comply with court orders to hand over documents.
The Full Federal Court has rejected German drug maker Boehringer Ingelheim’s appeal of ruling that shot down its opposition to Merck Sharp & Dohme’s patent application for an injectable anti-parasite drug for livestock.
The High Court has rejected plumbing company Repipe’s application to hear its case centred on the question of patent eligibility for computer-implemented inventions, saying the case was not an appropriate vehicle for special leave.